SPRTN and cancer: Indeed, the Target Discovery Institute (TDI), a collaborative cell-based phenotypic screening facility established at the University of Oxford, Nuffield Department of Medicine, to identify more tractable biological targets for potential drug development, has used the KCGS in a range of cancer screens, including combinatorial screens with proteins involved in DNA repair including ATM, SPRTN, FancD2, SETD2, and KMT2D, and pathways involved in ubiquitin-mediated proteolysis, and mRNA dysregulation.